VEGF Inhibitors Do Not Increase D-dimer Levels in Colorectal Cancer Patients Without Venous Thromboembolism: A Retrospective Non-inferiority Analysis

Overview

Journal In Vivo

Specialty Oncology

Date 2019 Oct 31

PMID 31662546

Citations 1

Authors

Hirokazu Toshima

Toshikazu Ikusue

Atsushi Hisamatsu

Kouji Kobayashi

Hiroo Ishida

Ken Shimada

Affiliations

Soon will be listed here.

Abstract

Background/aim: If VEGF inhibitors contribute to an increase in D-dimer levels, they may adversely affect the diagnosis of venous thromboembolism (VTE). Consequently, this retrospective study examined the effects of VEGF inhibitors on D-dimer levels in colorectal cancer patients.

Patients And Methods: A total of 104 colorectal cancer patients who received chemotherapy, were included in this study. To perform D-dimer analysis, patients were divided into two analysis targets: patients with VTE and without VTE. Statistical analysis included a natural logarithmic transformation of D-dimer data.

Results: In the D-dimer analysis of non-VTE patients, the natural logarithm D-dimer mean difference was -0.186, with a 95% CI of -0.525 to 0.154. The upper limit of the 95%CI (0.154) did not exceed the non-inferiority margin (Δ) of 0.199, and therefore met the non-inferiority criteria.

Conclusion: VEGF inhibitors don't contribute to increased D-dimer levels in colorectal cancer patients without VTE.

Citing Articles

Vascular endothelial growth factor and the risk of venous thromboembolism: a genetic correlation and two-sample Mendelian randomization study.

Zhang Q, Zhang X, Zhang J, Wang B, Tian Q, Meng X Thromb J. 2022; 20(1):67.

PMID: 36348399 PMC: 9644522. DOI: 10.1186/s12959-022-00427-6.

References

Meijer P, Haverkate F, Kluft C, Moerloose P, Verbruggen B, Spannagl M . A model for the harmonisation of test results of different quantitative D-dimer methods. Thromb Haemost. 2006; 95(3):567-72. DOI: 10.1160/TH05-01-0042. View

Galanaud J, Sevestre M, Pernod G, Genty C, Richelet S, Kahn S . Long-term outcomes of cancer-related isolated distal deep vein thrombosis: the OPTIMEV study. J Thromb Haemost. 2017; 15(5):907-916. DOI: 10.1111/jth.13664. View

Kamba T, McDonald D . Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007; 96(12):1788-95. PMC: 2359962. DOI: 10.1038/sj.bjc.6603813. View

Kearon C, Akl E, Ornelas J, Blaivas A, Jimenez D, Bounameaux H . Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016; 149(2):315-352. DOI: 10.1016/j.chest.2015.11.026. View

Khorana A . Venous thromboembolism and prognosis in cancer. Thromb Res. 2010; 125(6):490-3. PMC: 2878879. DOI: 10.1016/j.thromres.2009.12.023. View

Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu R . Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol. 2017; 29(1):44-70. DOI: 10.1093/annonc/mdx738. View

Wells P, Owen C, Doucette S, Fergusson D, Tran H . Does this patient have deep vein thrombosis?. JAMA. 2006; 295(2):199-207. DOI: 10.1001/jama.295.2.199. View

Cronin-Fenton D, Sondergaard F, Pedersen L, Fryzek J, Cetin K, Acquavella J . Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006. Br J Cancer. 2010; 103(7):947-53. PMC: 2965880. DOI: 10.1038/sj.bjc.6605883. View

Reber G, de Moerloose P . D-dimer assays for the exclusion of venous thromboembolism. Semin Thromb Hemost. 2001; 26(6):619-24. DOI: 10.1055/s-2000-13217. View

10.

Greilich P, Jessen M, Satyanarayana N, Whitten C, Nuttall G, Beckham J . The effect of epsilon-aminocaproic acid and aprotinin on fibrinolysis and blood loss in patients undergoing primary, isolated coronary artery bypass surgery: a randomized, double-blind, placebo-controlled, noninferiority trial. Anesth Analg. 2009; 109(1):15-24. DOI: 10.1213/ane.0b013e3181a40b5d. View

11.

Heit J, Silverstein M, Mohr D, Petterson T, OFallon W, Melton 3rd L . Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000; 160(6):809-15. DOI: 10.1001/archinte.160.6.809. View

12.

Verheul H, Pinedo H . Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer. 2007; 7(6):475-85. DOI: 10.1038/nrc2152. View

13.

Blom J, Doggen C, Osanto S, Rosendaal F . Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005; 293(6):715-22. DOI: 10.1001/jama.293.6.715. View

14.

Folkman J . Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285(21):1182-6. DOI: 10.1056/NEJM197111182852108. View

15.

Thaler J, Ay C, Pabinger I . Venous thromboembolism in cancer patients - risk scores and recent randomised controlled trials. Thromb Haemost. 2012; 108(6):1042-8. DOI: 10.1160/TH12-04-0241. View

16.

Dentali F, Pegoraro S, Barco S, Di Minno M, Mastroiacovo D, Pomero F . Clinical course of isolated distal deep vein thrombosis in patients with active cancer: a multicenter cohort study. J Thromb Haemost. 2017; 15(9):1757-1763. DOI: 10.1111/jth.13761. View

17.

Hurwitz H, Saltz L, Van Cutsem E, Cassidy J, Wiedemann J, Sirzen F . Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol. 2011; 29(13):1757-64. DOI: 10.1200/JCO.2010.32.3220. View

18.

Walker A, Card T, West J, Crooks C, Grainge M . Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases. Eur J Cancer. 2012; 49(6):1404-13. DOI: 10.1016/j.ejca.2012.10.021. View

19.

Ferroni P, Martini F, Portarena I, Massimiani G, Riondino S, La Farina F . Novel high-sensitive D-dimer determination predicts chemotherapy-associated venous thromboembolism in intermediate risk lung cancer patients. Clin Lung Cancer. 2012; 13(6):482-7. DOI: 10.1016/j.cllc.2012.03.005. View

20.

Ay C, Vormittag R, Dunkler D, Simanek R, Chiriac A, Drach J . D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol. 2009; 27(25):4124-9. DOI: 10.1200/JCO.2008.21.7752. View